Bicycle Therapeutics to Participate in Upcoming Investor Conferences
October 30 2023 - 6:00AM
Business Wire
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company
pioneering a new and differentiated class of therapeutics based on
its proprietary bicyclic peptide (Bicycle®) technology, today
announced that management will participate in the following
investor conferences in November:
- TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday,
November 3, 2023; fireside chat at 10:00 a.m. ET
- Jefferies London Healthcare Conference on Wednesday, November
15, 2023; fireside chat at 11:00 a.m. ET
Live webcasts of the fireside chats will be accessible in the
Investors section of Bicycle’s website at
www.bicycletherapeutics.com. Archived replays of the webcasts will
be available following the fireside chat dates.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical
company developing a novel class of medicines, referred to as
Bicycles, for diseases that are underserved by existing
therapeutics. Bicycles are fully synthetic short peptides
constrained with small molecule scaffolds to form two loops that
stabilize their structural geometry. This constraint facilitates
target binding with high affinity and selectivity, making Bicycles
attractive candidates for drug development. The company is
evaluating BT8009, a Bicycle Toxin Conjugate (BTC™) targeting
Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting
EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing
CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718,
a BTC that targets MT1-MMP, is being investigated in an ongoing
Phase 1/2a clinical trial sponsored by the Cancer Research UK
Centre for Drug Development. Bicycle Therapeutics is headquartered
in Cambridge, UK, with many key functions and members of its
leadership team located in Cambridge, Mass. For more information,
visit bicycletherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231030608322/en/
Investors: Stephanie Yao SVP, Investor Relations and
Corporate Communications ir@bicycletx.com 857-523-8544
Media: Argot Partners Sarah Sutton media@bicycletx.com
212-600-1902
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From May 2024 to Jun 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Jun 2023 to Jun 2024